WO2007076655A1 - METHOD FOR SYNTHESIS OF CHOLEST-3β,5α,6β,19-TETRAHYDROXY-24-ONE AND ITS DERIVATIVES - Google Patents

METHOD FOR SYNTHESIS OF CHOLEST-3β,5α,6β,19-TETRAHYDROXY-24-ONE AND ITS DERIVATIVES Download PDF

Info

Publication number
WO2007076655A1
WO2007076655A1 PCT/CN2006/001627 CN2006001627W WO2007076655A1 WO 2007076655 A1 WO2007076655 A1 WO 2007076655A1 CN 2006001627 W CN2006001627 W CN 2006001627W WO 2007076655 A1 WO2007076655 A1 WO 2007076655A1
Authority
WO
WIPO (PCT)
Prior art keywords
add
reaction
solution
reduced pressure
under reduced
Prior art date
Application number
PCT/CN2006/001627
Other languages
French (fr)
Chinese (zh)
Inventor
Guangmei Yan
Jingxia Zhang
Pengxin Qiu
Yijun Huang
Qun Li
Original Assignee
Sun Yat-Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat-Sen University filed Critical Sun Yat-Sen University
Priority to AU2006332419A priority Critical patent/AU2006332419A1/en
Publication of WO2007076655A1 publication Critical patent/WO2007076655A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Definitions

  • the present invention relates to a method for synthesizing cholestyl-3?,5?,6?,19-tetrahydroxy-24-ketone (structures such as I) and derivatives.
  • 24-methylene-cholesterol-35 a, 6 ⁇ , 19-tetraol is a polyhydroxysteroid compound isolated from the soft corals Nephthea albida and N. tiexieralv erseveldt. Wang Guiyang, Li Fengying, Zeng Yongmei et al., Chemical Journal of Chinese Universities, 1992, 13, 623-627). The compound has strong killing ability on human rectal cancer cells, human lung cancer cells and murine lymphoid cancer cells (Chang- Yih Duh, Shang-Kwei, Mei-Jen Clu et al., J. Nat.
  • An object of the present invention is to provide a method for synthesizing cholestyl-3?,5?,6?,19-tetrahydroxy-24-one and derivatives.
  • the synthesis method of the invention uses porcine deoxycholic acid as a raw material to prepare 3 3-acetoxy-cholesteryl 5-
  • the ene-24-acid is prepared by reacting with thionyl chloride to prepare choline chloride, which is reacted with isopropyl cadmium reagent under ultrasonic irradiation to obtain 3 ⁇ -acetoxy-cholesteryl-5-ene-24-one, and then Reaction of bromosuccinimide/perchloric acid aqueous solution to obtain 3 ⁇ -acetoxy-cholesteryl-5 ⁇ -bromo-6 ⁇ -hydroxy-24-ketone, diacetoxyiodobenzene oxidation ring Generation of 3 ⁇ -acetoxy-cholesteryl-5?-bromo-6,19-epoxy-24-ketone, followed by reduction with zinc powder/glacial acetic acid system or zinc powder/alcohol system to form 3 ⁇ , 19-diacetyl Oxy-cholesteryl 5-alkenyl-2-
  • the concentration of the benzene solution in the step (2) is 25 to 45%, the amount of the thionyl chloride is 1.0 to 2.0 times the number of moles of II; the amount of the magnesium powder in the step (3) is II.
  • the molar amount of the organic solvent is 1.2 to 3.0 times; the organic solvent in the step (4) is tetrahydrofuran or dioxane; the oxidizing agent in the step (5) is diacetoxyiodobenzene or lead tetraacetate; in the step (7)
  • the oxidizing agent is potassium permanganate/copper sulfate or m-chloroperbenzoic acid; the oxidizing agent in the step (8) is 30% hydrogen peroxide.
  • the synthetic method of the invention has scientific and reasonable reaction route and high yield of the synthetic compound, and the synthesized intermediates are cholesteric-3 ⁇ , 5 ⁇ , 6 ⁇ , 19-tetrahydroxy-24-one, 24-methylene-cholesteryl-3 ⁇ , 5 ⁇ , 6 ⁇ , 19—four Alcohol; and cholesteric-3 ⁇ , 5 ⁇ , 6 ⁇ , 19-tetrahydroxy-; 24-biguanide have significant protective effects on low potassium-induced neuronal apoptosis cells.
  • I represents cholesteryl-3 ⁇ ,5 ⁇ ,60,19-tetrahydroxy-24-one
  • II represents 24-methylene-cholesteryl-3 ⁇ ,5 ⁇ ', 6 ⁇ ,19 Tetrahydrin
  • III represents cholestyl-3 ⁇ , 5 ⁇ , 6 ⁇ , 19-tetrahydroxy-24-biguanide
  • IV represents 3 ⁇ -acetoxy-cholesteryl 5-alkenyl 24-acid
  • V represents 3 ⁇ -Acetoxy-cholesteryl-5-ene-24-one
  • VI represents 3?-acetoxy-cholesteryl-5?-bromo-6?-hydroxy-24-one
  • VII represents 3 acetoxy-cholesterium-5?
  • VDI stands for 3 ⁇ , 19-diacetoxy-cholester-5-ene-24'-ketone
  • Ka stands for 3 ⁇ , 19-diacetoxy-chol ⁇ 5, 6 ⁇ -epoxy-24-ketone
  • Kb stands for 3 ⁇ , 19-diacetoxy-cholesteryl-5,6 ⁇ -epoxy-24-one
  • X stands for 3 ⁇ , 19-diacetoxy-chol ⁇ 5,6-dihydroxy-24-ketone.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Abstract

A synthesis process of cholest-3β,5α,6β,19-tetrahydroxy-24-one and its derivatives includes the steps of: synthesis of 3β-acetoxy-cholest-5-en-24-acid with hyodesoxycholic acid as the starting material; synthesis of cholenic acid chloride by reaction with thionyl chloride; reaction with isopropylcadmium reagent under ultrasonic irradiation to produce 3β-acetoxy-cholest-5-en-24-one; then reaction with N-bromosuccinimide/water solution of perchloric acid system to obtain 3β-acetoxy-cholest-5α-bromo-6β-hydroxy-24-one; reaction with diacetoxy iodobenzene to give 3β-acetoxy-cholest-5α-bromo-6β,19-epoxy-24-one; reduction with Zn powder/glacial acetic acid system to give 3β,19-diacetoxy-cholest-5-en-24-one; oxidation of the double bond at position 5 and 6; then hydrolysis to produce cholest-3β,5α,6β,19-tetrahydroxy-24-one; finally reaction with methyltriphenylphosphonium bromide to produce 24-methylene-cholest-3β,5α,6β,19-tetraol; and reaction with hydrazine to give cholest-3β,5α,6β,19-tetrahydroxy-24-dihydrazone. The synthesis process according to the invention has the characteristic of lower price, material availability, scientific and reasonable synthetic routes, higher yield, and the like. The target compounds have significantly protective effect on neuronal apoptosis evoked by low K+.

Description

胆甾— 3 β, 5 α , 6 β , 19—四羟基—24—酮及衍生物的合成方法 技术领域 Method for synthesizing cholesteric-3β, 5α, 6β, 19-tetrahydroxy-24-ketone and derivatives
本发明涉及胆甾一 3β,5α, 6β,19—四羟基一 24—酮 (结构如 I ) 及衍生物的 合成方法。  The present invention relates to a method for synthesizing cholestyl-3?,5?,6?,19-tetrahydroxy-24-ketone (structures such as I) and derivatives.
背景技术 Background technique
24-亚甲基一胆甾一 3 5 a, 6 β , 19—四醇(结构如式 II )是从南海软珊瑚 Nephthea albida及 N.tiexieralv erseveldt中分离得到的一种多羟基甾体化合物(王 贵阳, 李凤英, 曾陇梅等, 高等学校化学学报, 1992, 13, 623-627)。 该化合物对 人体直肠癌细胞、 人体肺癌细胞、 鼠类淋巴癌细胞均具有较强的杀伤能力 ( Chang- Yih Duh, Shang-Kwei, Mei -Jen Cl u et al., J. Nat. Prod., 1998, 61 , 1022-1024) , 对多种炎症有显著的抗炎作用 (王正濂, 许实波, 刘清等, 热带海 洋, 1999, 18, 27-32), 该化合物对低钾诱导的神经元凋亡细胞有显著的保护作 用。  24-methylene-cholesterol-35 a, 6 β, 19-tetraol (structure such as formula II) is a polyhydroxysteroid compound isolated from the soft corals Nephthea albida and N. tiexieralv erseveldt. Wang Guiyang, Li Fengying, Zeng Yongmei et al., Chemical Journal of Chinese Universities, 1992, 13, 623-627). The compound has strong killing ability on human rectal cancer cells, human lung cancer cells and murine lymphoid cancer cells (Chang- Yih Duh, Shang-Kwei, Mei-Jen Clu et al., J. Nat. Prod., 1998, 61, 1022-1024), has significant anti-inflammatory effects on a variety of inflammations (Wang Zhengyi, Xu Shibo, Liu Qing et al, Tropical Ocean, 1999, 18, 27-32), the compound for low potassium induced neuronal withering Dead cells have a significant protective effect.
Figure imgf000003_0001
Figure imgf000003_0001
Π  Π
该化合物在海洋生物中的含量极低,直接用海洋生物原料提取目前尚存在很 多问题,研究合成该化合物具有很高的药用价值。合成该化合物的中间体胆甾一 The content of this compound in marine organisms is extremely low. There are still many problems in the direct extraction of marine biological raw materials. The synthesis of this compound has high medicinal value. Intermediate cholesteric synthesis of the compound
3β,5α, 6β,19一四羟基一 24—酮及含氮衍 '生物对低钾诱导的神经元凋亡细胞有显 著的保护作用。 3β, 5α, 6β, 19-tetrahydroxy- 24-ketone and nitrogen-containing derivatives have significant protective effects on hypokalemia-induced neuronal apoptotic cells.
发明内容 Summary of the invention
本发明的目的是提供一种胆甾一 3β,5α, 6β,19—四羟基一 24—酮及衍生物的 合成方法。  SUMMARY OF THE INVENTION An object of the present invention is to provide a method for synthesizing cholestyl-3?,5?,6?,19-tetrahydroxy-24-one and derivatives.
本发明的合成方法以猪去氧胆酸为原料, 制备 3 3—乙酰氧基一胆甾一 5— 烯一 24—酸通过和氯化亚砜反应制备成胆 酰氯,超声波辐射下和异丙基镉试剂 反应得 3 β—乙酰氧基一胆甾一 5—烯一 24—酮, 再与 Ν—溴代丁二酰亚胺 /高氯 酸水溶液体系中反应得到 3 β—乙酰氧基一胆甾一 5 α—溴一 6 β—羟基一 24— 酮, 二乙酰氧基碘代苯氧化关环生成 3 ^—乙酰氧基一胆甾一 5 α—溴一 6, 19 一环氧一 24—酮, 接着用锌粉 /冰醋酸体系或锌粉 /醇体系还原生成 3 β, 19一二 乙酰氧基一胆甾一 5—烯一 24—酮, 再通过碱解得胆甾一 5—烯一 3 β, 19一羟基 一 24—酮; 用氧化剂氧化、 水解反应得胆甾 _3β,5α, 6β,19一四羟基一 24—酮; 和甲基三苯基溴化膦反应合成 24—亚甲基一胆甾一 3 β, 5 α, 6 β,19—四醇; 和肼反应合成胆甾— 3β,5α, 6β,19—四羟基一 24—双腙。 反应路线如下图所示: The synthesis method of the invention uses porcine deoxycholic acid as a raw material to prepare 3 3-acetoxy-cholesteryl 5- The ene-24-acid is prepared by reacting with thionyl chloride to prepare choline chloride, which is reacted with isopropyl cadmium reagent under ultrasonic irradiation to obtain 3β-acetoxy-cholesteryl-5-ene-24-one, and then Reaction of bromosuccinimide/perchloric acid aqueous solution to obtain 3β-acetoxy-cholesteryl-5 α-bromo-6β-hydroxy-24-ketone, diacetoxyiodobenzene oxidation ring Generation of 3^-acetoxy-cholesteryl-5?-bromo-6,19-epoxy-24-ketone, followed by reduction with zinc powder/glacial acetic acid system or zinc powder/alcohol system to form 3β, 19-diacetyl Oxy-cholesteryl 5-alkenyl-2-ketone, and then choline-5-alkenyl-2-keto-ketone by alkali hydrolysis; oxidizing and hydrolyzing with oxidizing agent to obtain cholesteric _3β, 5α , 6β,19-tetrahydroxy-24-ketone; and methyltriphenylphosphonium bromide to synthesize 24-methylene-cholesteryl-3β, 5α, 6β,19-tetraol; Cholesterol - 3β, 5α, 6β, 19-tetrahydroxy-24-biguanide. The reaction route is shown below:
Figure imgf000004_0001
Figure imgf000004_0001
I . 胆甾一 3 β,5 α, 6 19—四羟基—24—酮; Π.24—亚甲基一胆甾一 3 β, 5 α, 6 β, 19—四醇; I. cholestyl-3 β,5 α, 6 19-tetrahydroxy-24-ketone; Π.24-methylene-cholesterol-3 β, 5 α, 6 β, 19-tetraol;
III. 胆甾一 3β,5α, 6β,19—四羟基一24—双腙;  III. Cholesterol-3β,5α, 6β,19-tetrahydroxy-24-biguanide;
IV.3 β一乙酰氧基一胆甾一 5—烯一 ί4一酸;  IV.3 β-acetoxy-cholesteryl 5-ene- 44-acid;
V.3 β—乙酰氧基一胆甾一 5—烯一 24—酮;  V.3 β-acetoxy-cholesteryl-5-ene-24-one;
VI.3 β—乙酰氧基一胆甾一 5α—溴一 6 β—羟基 _24  VI.3 β-acetoxy-cholesteryl-5α-bromo-6β-hydroxy _24
W.3 β—乙酰氧基一胆甾一 5 α—溴一 6 β, 19—环氧  W.3 β-acetoxy-cholesterol-5 α-bromo-6β, 19-epoxy
珊.3β, 19一二乙酰氧基 胆甾一 5—烯一 24—酮;  Shan.3β, 19-diacetoxycholine-5-ene-24-one;
Κ .3β 19—二乙酰氧基一胆甾一 5, 6β—环氧—24—酮;  Κ .3β 19-diacetoxy-cholesteryl-5,6β-epoxy-24-ketone;
Kb.3β 19一二乙酰氧基一胆甾一 5, 6ci—环氧  Kb.3β 19-diacetoxy-cholesteryl-5, 6ci-epoxy
Χ.3β, 二乙酰氧基一胆甾一 5, 6—二羟基一24—酮。  Β.3β, diacetoxy-cholesteryl-5,6-dihydroxy-24-one.
本发明的合成方法的具体步骤是:  The specific steps of the synthetic method of the present invention are:
(1) IV参照文献 (Bharuclia , Buckley GC, Cross CK, et al. Can J Chem., 1955,34: 982-990.) 合成;  (1) IV reference (Bharuclia, Buckley GC, Cross CK, et al. Can J Chem., 1955, 34: 982-990.) Synthesis;
(2) 将 IV溶于无水苯加入氯化亚砜, 加入催化量的吡啶, 在室温下搅拌 2〜 4小时, 减压浓缩至干, 再补加苯继续浓缩, 带出残留的氯化亚砜, 得黄色粘稠 的液体;  (2) Add IV to anhydrous benzene to thionyl chloride, add a catalytic amount of pyridine, stir at room temperature for 2 to 4 hours, concentrate to dryness under reduced pressure, and add benzene to continue concentration to bring out residual chlorination. Sulfoxide, a yellow viscous liquid;
(3) 称取干燥镁粉, 加入无水乙醚,'滴加异溴丙烷 /无水乙醚溶液, 加完后 超声辐射 15〜30分钟, 冷却后分批加入氯化镉, 在 25〜40°C下在超声波辐射下 搅拌, 冰浴冷却下, 将上步产物的 30〜40%无水苯溶液慢慢滴加到反应体系中, 滴完后继续超声波辐射回流 1〜2小时, 冰浴冷却后, 滴加 1: 1盐酸水溶液, 用 苯萃取, 苯层用蒸馏水洗至中性, 干燥, 减压浓缩, 硅胶柱层析, 得白色固体 V; (3) Weigh dry magnesium powder, add anhydrous ether, 'drop add isobromopropane / anhydrous ether solution, add ultrasonic radiation after 15~30 minutes, add cadmium chloride in batches after cooling, at 25~40° Stir under ultrasonic irradiation, and slowly add 30~40% anhydrous benzene solution of the above step product to the reaction system after cooling. After the completion of the dropping, continue ultrasonic wave reflux for 1~2 hours, cool in ice bath. After that, a 1:1 aqueous solution of hydrochloric acid is added dropwise, and extracted with benzene, and the benzene layer is washed with distilled water until neutral, dried, concentrated under reduced pressure, and purified by silica gel column chromatography
(4) 取白色固体 V, 加入有机溶剂溶解, 再加入 HC104及水, 然后在避光 条件下分批加入 N—丁二酰亚胺, 控制温度低于 10°C, 之后在 15〜20°C下反应 1〜2小时, 向反应液中加入 10%Na2S2O8 水溶液, 分层后, 上层浓缩, 下层用 C¾C12萃取, 合并有机层, 用饱和 NaHC03溶液洗漆, 再用蒸馏水洗涤至中性, 干燥, 减压浓缩, 硅胶柱层析, 得白色同体 VI; (4) Take a white solid V, add organic solvent to dissolve, add HC10 4 and water, then add N-succinimide in portions in the dark, control the temperature below 10 ° C, then at 15~20 The reaction was carried out at ° C for 1 to 2 hours, and a 10% aqueous solution of Na 2 S 2 O 8 was added to the reaction mixture. After layering, the upper layer was concentrated, and the lower layer was extracted with C3⁄4C1 2 , and the organic layer was combined and washed with a saturated NaHC0 3 solution. Wash with distilled water until neutral, dry, concentrated under reduced pressure, silica gel column chromatography, to obtain white homo-VI;
(5) 取化合物 VI, 溶入环已烷 /苯混合液, 加入氧化剂, 20〜40°C搅拌下, 紫外灯照射 7〜8小时, 反应液依次用 10%硫代硫酸钠水溶液, 饱和 NaHC03溶 液及蒸镏水洗涤至中性, 干燥, 减压浓缩得浅黄色化合物 W; (6)取化合物厦加入冰醋酸溶解, 加入锌粉, 搅拌回流 20〜24小时; 趁热 抽滤,滤液用二氯甲垸萃取,萃取液分别用饱和碳酸氢钠溶液及蒸馏水洗至中性, 干燥, 减压浓缩, 硅胶柱层析, 得浅黄色粘稠液体 ; (5) Take compound VI, dissolve in cyclohexane/benzene mixture, add oxidant, stir at 20~40 °C, irradiate with UV lamp for 7~8 hours, and then use 10% aqueous sodium thiosulfate solution, saturated NaHC0. 3 solution and distilled water to wash to neutral, dry, concentrated under reduced pressure to give a pale yellow compound W; (6) Take the compound and add glacial acetic acid to dissolve, add zinc powder, stir and reflux for 20~24 hours; heat and filter, the filtrate is extracted with dichloromethane, and the extract is washed with saturated sodium bicarbonate solution and distilled water until neutral. , drying, concentration under reduced pressure, silica gel column chromatography, to obtain a pale yellow viscous liquid;
(7)取化合物 加入二氯甲烷溶解, 加入氧化剂, 室温下搅拌, 减压除去二 氯甲垸,渣块用乙酸乙酯溶解,然后加 10%亚硫酸钠溶液洗涤至无色,水洗至中 性, 干燥, 减压浓缩, 得白色固体 Ka, 将其加入丙酮溶解, 加入高氯酸, 室温 下搅拌, 调 pH至中性, 减压蒸去丙酮, '用二氯甲垸萃取, 干燥, 减压浓缩, 得 白色固体 X;  (7) The compound is dissolved in dichloromethane, added with an oxidizing agent, stirred at room temperature, and the dichloromethane is removed under reduced pressure. The residue is dissolved in ethyl acetate, and then washed with a 10% sodium sulfite solution until colorless, washed with water until neutral. Dry, concentrate under reduced pressure to give a white solid Ka, dissolve it in acetone, add perchloric acid, stir at room temperature, adjust pH to neutral, distill off acetone under reduced pressure, 'extract with dichloromethane, dry, decompress Concentrated to give a white solid X;
(8) 取化合物 I加入 88%甲酸溶解, 沸水浴加热 5分钟, 冷却至室温, 加 入氧化剂, 室温放置 24小时, 用水稀释后, 用乙酸乙酯萃取, 然后加 10%亚硫 酸钠溶液洗涤至无色, 水洗至中性, 干蟬, 减压浓缩, 得白色固体 Kb;  (8) Compound I was dissolved in 88% formic acid, heated in a boiling water bath for 5 minutes, cooled to room temperature, added with oxidizing agent, allowed to stand at room temperature for 24 hours, diluted with water, extracted with ethyl acetate, and then washed with 10% sodium sulfite solution until colorless. , washed to neutral, dried, concentrated under reduced pressure to give a white solid Kb;
(9)将上步产物 Kb或 X溶解在甲醇中,加入浓度为 3 %的氢氧化钾醇溶液, 加热回流 15〜30分钟, 调 pH为中性, 减压蒸馏除去甲醇, 乙酸乙酯萃取, 有 机层干燥, 减压蒸去溶剂, 得浅黄色固体, 硅胶柱层析, 得白色固体 I;  (9) The upper step product Kb or X is dissolved in methanol, and a 3% potassium hydroxide alcohol solution is added thereto, and the mixture is heated under reflux for 15 to 30 minutes to adjust the pH to neutrality, and methanol is distilled off under reduced pressure, and ethyl acetate is extracted. , the organic layer is dried, the solvent is evaporated under reduced pressure to give a pale yellow solid.
( 10) 将甲基三苯基溴化膦加入无水四氢呋喃溶液中, 注入正丁基锂, 注入 量以甲基三苯基溴化膦刚好溶解为宜, 室温下搅拌反应 4〜6小时, 将上步中的 I加入反应体系,继续反应 2〜3小时,将反应液迅速倒入饱和的氯化铵溶液中, 用乙醚萃取, 醚层干燥, 减压蒸去溶剂, 得浅黄色固体, 硅胶柱层析, 得白色固 体 II;  (10) Add methyltriphenylphosphonium bromide to an anhydrous tetrahydrofuran solution, and inject n-butyllithium. The amount of the injection is preferably dissolved in methyltriphenylphosphonium bromide. The reaction is stirred at room temperature for 4 to 6 hours. The I in the above step is added to the reaction system, and the reaction is continued for 2 to 3 hours. The reaction solution is poured into a saturated ammonium chloride solution, extracted with diethyl ether, the ether layer is dried, and the solvent is evaporated to give a pale yellow solid. Silica gel column chromatography gave white solid II;
( 11 ) 将 I加入乙醇溶解, 加入肼的水溶液中, 解热回流, 减压蒸去溶剂, 加入水, 调 pH为中性, 乙酸乙酯萃取, '得白色固体, 硅胶柱层析, 得白色固体 III。  (11) I was dissolved in ethanol, added to an aqueous solution of hydrazine, refluxed under reduced pressure, and the solvent was evaporated under reduced pressure. Water was added, and the mixture was adjusted to neutral, and ethyl acetate was evaporated to give a white solid. White solid III.
上述反应步骤中, 步骤(2)中 II的苯溶液的浓度是 25〜45%, 氯化亚砜的 量是 II的摩尔数的 1.0〜2.0倍; 步骤(3 ) 中镁粉的量是 II的摩尔数的 1.2〜3.0 倍; 步骤(4) 中的有机溶剂为四氢呋喃或二氧六环; 步骤(5) 中的氧化剂为二 乙酰氧基碘代苯或四醋酸铅; 步骤(7)中的氧化剂为高锰酸钾 /硫酸铜或间氯过 苯甲酸; 步骤 (8) 中的氧化剂为 30%双氧水。  In the above reaction step, the concentration of the benzene solution in the step (2) is 25 to 45%, the amount of the thionyl chloride is 1.0 to 2.0 times the number of moles of II; the amount of the magnesium powder in the step (3) is II. The molar amount of the organic solvent is 1.2 to 3.0 times; the organic solvent in the step (4) is tetrahydrofuran or dioxane; the oxidizing agent in the step (5) is diacetoxyiodobenzene or lead tetraacetate; in the step (7) The oxidizing agent is potassium permanganate/copper sulfate or m-chloroperbenzoic acid; the oxidizing agent in the step (8) is 30% hydrogen peroxide.
本发明的合成方法的反应路线科学合理、合成物的产率高,合成的中间体胆 甾一 3β,5α, 6β,19—四羟基一 24—酮, 24—亚甲基一胆甾一 3 β ,5 α, 6 β ,19—四 醇; 及胆甾—3β,5α, 6β, 19—四羟基一; 24—双腙对低钾诱导的神经元调亡细胞 具有显著的保护作用。 The synthetic method of the invention has scientific and reasonable reaction route and high yield of the synthetic compound, and the synthesized intermediates are cholesteric-3β, 5α, 6β, 19-tetrahydroxy-24-one, 24-methylene-cholesteryl-3 β , 5 α, 6 β , 19—four Alcohol; and cholesteric-3β, 5α, 6β, 19-tetrahydroxy-; 24-biguanide have significant protective effects on low potassium-induced neuronal apoptosis cells.
具体实施方式 detailed description
以下实施例用以说明本发明, 但本发明的保护范围并不仅限以下实施例。除 非有特别说明, 以下实施例中: I代表胆甾一 3β,5α , 60, 19—四羟基一24— 酮; II代表 24—亚甲基一胆甾一 3β,5α', 6β,19一四醇; III代表 胆甾一 3 β, 5 α, 6β, 19—四羟基一 24—双腙; IV代表 3 β—乙酰氧基一胆甾一 5—烯一 24— 酸; V代表 3 β—乙酰氧基一胆甾一 5—烯一 24—酮; VI代表 3β—乙酰氧基一 胆甾— 5α—溴一 6β—羟基一 24—酮; VII代表 3 乙酰氧基一胆甾—5α—溴 一 6β, 19一环氧一24—酮; VDI代表 3β,, 19—二乙酰氧基一胆甾一 5—烯一 24' —酮; Ka代表 3β, 19—二乙酰氧基—胆甾一 5, 6β—环氧一24—酮; Kb代 表 3β, 19—二乙酰氧基一胆甾一 5, 6α _环氧一 24—酮; X代表 3β, 19—二 乙酰氧基—胆甾一 5, 6—二羟基一 24—酮。  The following examples are intended to illustrate the invention, but the scope of protection of the invention is not limited to the following examples. Unless otherwise stated, in the following examples: I represents cholesteryl-3β,5α,60,19-tetrahydroxy-24-one; II represents 24-methylene-cholesteryl-3β,5α', 6β,19 Tetrahydrin; III represents cholestyl-3 β, 5 α, 6β, 19-tetrahydroxy-24-biguanide; IV represents 3 β-acetoxy-cholesteryl 5-alkenyl 24-acid; V represents 3 β -Acetoxy-cholesteryl-5-ene-24-one; VI represents 3?-acetoxy-cholesteryl-5?-bromo-6?-hydroxy-24-one; VII represents 3 acetoxy-cholesterium-5? - bromo-6β, 19-epoxy-24-ketone; VDI stands for 3β, 19-diacetoxy-cholester-5-ene-24'-ketone; Ka stands for 3β, 19-diacetoxy-chol甾5, 6β-epoxy-24-ketone; Kb stands for 3β, 19-diacetoxy-cholesteryl-5,6α-epoxy-24-one; X stands for 3β, 19-diacetoxy-chol甾5,6-dihydroxy-24-ketone.
实施例 1 Example 1
胆甾一 3β,5α, 6β, 19一四羟基一 24—酮的合成  Synthesis of cholesteric 3β,5α, 6β, 19-tetrahydroxy-24-ketone
(1) 取化合物 (V) 100克, 加入 300ml苯, 20 ml氯化亚砜, 1ml吡啶, 在室温下搅拌 2 小时, 减压浓缩至干, 除去残留的氯化亚砜, 得酰氯化合物用 200 ml苯溶解, 备用。 取 20克干燥的镁粉, 加入 60 ml无水乙醚, 在 60%超声 波辐射下滴注 73 ml异溴丙垸的无水乙醚溶液, 加完继续超声 15〜30分钟, 冷 却后分四批加入 78克氯化镉, 在 25〜40'°C下开 60%超声波振荡半小时。冰水冷 却下, 慢慢滴加酰氯的苯溶液, 滴毕继续超声回流 2小时。 加冰水冷冻 30分钟 后, 滴加 150ml (1: 1) 盐酸水溶液, 用苯萃取三次, 苯层用蒸馏水洗至中性, 无水硫酸钠干燥, 减压浓縮, 硅胶柱层析, 得白色固体 (VI)。  (1) Take 100 g of the compound (V), add 300 ml of benzene, 20 ml of thionyl chloride, 1 ml of pyridine, stir at room temperature for 2 hours, and concentrate to dryness under reduced pressure to remove residual thionyl chloride to obtain an acid chloride compound. 200 ml of benzene was dissolved and used. Take 20 grams of dry magnesium powder, add 60 ml of anhydrous ether, instill 73 ml of isobromopropene in anhydrous ether solution under 60% ultrasonic irradiation, continue to ultrasonic for 15 to 30 minutes, and then add in four batches after cooling. 78 g of cadmium chloride was shaken at 60 to 40 ° C for 60% ultrasonic wave for half an hour. While the ice water was cold, the benzene solution of the acid chloride was slowly added dropwise, and the ultrasonic wave was further refluxed for 2 hours. After chilling with ice water for 30 minutes, 150 ml (1:1) aqueous hydrochloric acid solution was added dropwise, and extracted with benzene three times. The benzene layer was washed with distilled water until neutral, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. White solid (VI).
(2) 取白色固体 (VI) 20克, 加入 20mL四氢呋喃溶解, 加入适量 HC104 及水,然后在避光条件下降 20克 N—丁二酰亚胺分批加入到反应液中, 控制温 度低于 10°C, 之后在 15〜20°C下反应 2小时。 向反应液中加入 10%Na2S2O8水 溶液, 分层后, 用 CH2C12萃取, 合并有机层, 用饱和 NaHC03溶液洗涤, 再用 蒸镏水洗涤至中性, 无水硫酸钠干燥, 减压浓缩,硅胶柱层析,得白色固体(W)。 (2) Take 20g of white solid (VI), add 20mL of tetrahydrofuran to dissolve, add appropriate amount of HC10 4 and water, then add 20g of N-succinimide in the dark to the reaction solution in batches, the temperature is low. The reaction was carried out at 10 ° C for 2 hours at 15 to 20 ° C. A 10% aqueous solution of Na 2 S 2 O 8 was added to the reaction mixture, and the layers were separated, and then extracted with CH 2 C 2 2 , and the organic layer was combined, washed with a saturated NaHCO 3 solution, and washed with distilled water to neutral, anhydrous sulfuric acid The organic layer was dried (MgSO4).
(3)取化合物 (VII) 5克, 溶入 lOOOmL环已烷 /苯混合液, 加入 4克二乙酰 氧基碘代苯, 2.8克碘, 搅拌下, 40°C下紫外灯照射 2小时, 反应液依次用 10% 硫代硫酸钠水溶液, 饱和 NaHC03溶液及蒸馏水洗涤至中性, 无水硫酸钠干燥, 减压浓缩得浅黄色粘稠状化合物 ( )。 (3) Take 5 g of compound (VII), dissolve it into 1000 mL of cyclohexane/benzene mixture, and add 4 g of diacetyl. Oxyiodobenzene, 2.8 g of iodine, irradiated with a UV lamp at 40 ° C for 2 hours while stirring, and the reaction solution was washed with a 10% aqueous sodium thiosulfate solution, a saturated NaHC0 3 solution and distilled water to neutral, anhydrous sodium sulfate. Dry and concentrate under reduced pressure to give a pale yellow viscous compound ().
(4)取化 2克合物(珊)加入 40冰醋酸溶解, 加入 6锌粉, 搅拌回流 20〜 24小时。 趁热抽滤, 滤液到入 5倍量水中, 用二氯甲烷萃取, 萃取液分别用饱 和碳酸氢钠溶液及蒸馏水洗至中性, 无水硫酸钠干燥, 减压浓缩, 硅胶柱层析, 得浅黄色粘稠液体 (111)。  (4) Take 2 gram of compound (Shan), add 40 glacial acetic acid to dissolve, add 6 zinc powder, and stir to reflux for 20 to 24 hours. The mixture was filtered while hot, and the filtrate was poured into 5 times of water and extracted with dichloromethane. The extract was washed with saturated sodium bicarbonate and distilled water to dryness, dried over anhydrous sodium sulfate, A pale yellow viscous liquid (111).
(5) 取化合物 (珊)加入二氯甲垸溶解 (浓度约为 2.5~10%) ,加入结晶硫 酸铜及高锰酸钾混合物粉末, 再加入适量叔丁醇及水,室温下搅拌 2小时。 减压 除去二氯甲烷, 渣块用乙酸乙酯溶解, 然后加 10%亚硫酸钠溶液洗涤至无色, 水 洗至中性, 无水硫酸钠干燥, 减压浓缩, 得白色固体(Ka)。将其加入丙酮溶解, 加入适量高氯酸 , 室温下搅拌 24小时,用饱和碳酸氢钠溶液调 pH至中性,减 压蒸去丙酮, 用二氯甲烷萃取, 无水硫酸钠干燥, 减压浓缩, 得白色固体(X)。  (5) Take the compound (Shan) dissolved in dichloromethane (concentration is about 2.5~10%), add the mixture of crystalline copper sulfate and potassium permanganate mixture, add appropriate amount of t-butanol and water, stir at room temperature for 2 hours. . The methylene chloride was removed under reduced pressure, and the residue was crystallised from ethyl acetate (EtOAc). Adding to acetone, adding appropriate amount of perchloric acid, stirring at room temperature for 24 hours, adjusting the pH to neutral with saturated sodium bicarbonate solution, distilling off acetone under reduced pressure, extracting with dichloromethane, drying over anhydrous sodium sulfate, decompression Concentration gave a white solid (X).
(6)将上步产物 (X) lg加到 500mL3%的氢氧化钾甲醇溶液, 加热回流 30分钟, 用 5%盐酸调整溶液的 pH为中性, 减压蒸馏除去甲醇, 乙酸乙酯萃取 三次, 有机层合并用无水硫酸钠干燥, 减压蒸去溶剂, 得浅黄色固体, 硅胶柱层 析, 得白色固体(1)。  (6) Add the above product (X) lg to 500 mL of 3% potassium hydroxide methanol solution, heat to reflux for 30 minutes, adjust the pH of the solution to neutral with 5% hydrochloric acid, distill off methanol under reduced pressure, and extract with ethyl acetate three times. The organic layer was dried over anhydrous sodium sulfate (MgSO4).
实施例 2 Example 2
胆甾一 3e,5a , 6β,19—四羟基一 4一酮的合成  Synthesis of cholestyl-3e,5a, 6β,19-tetrahydroxy-4-one
(1)〜(4) 与实施例 1的步骤 (1) ~ (4)相同。  (1) to (4) The same as steps (1) to (4) of the first embodiment.
(5)取化合物(珊)加入二氯甲烷溶解(浓度约为 2.5~10%), 加入间氯过 氧苯甲酸, 室温下搅拌 2小时。减压除去二氯甲烷, 渣块用乙酸乙酯溶解, 然后 加 10%亚硫酸钠溶液洗涤至无色, 水洗至中性, 无水硫酸钠干燥, 减压浓缩, 得 白色固体(Ka)。将其加入丙酮溶解,加入适量高氯酸 ,室温下搅拌 24小时,用 饱和碳酸氢钠溶液调 pH至中性,减压蒸去丙酮, 用二氯甲烷萃取, 无水硫酸钠 干燥, 减压浓缩, 得白色固体(X)。  (5) The compound (Shan) was dissolved in dichloromethane (concentration: about 2.5 to 10%), and m-chloroperoxybenzoic acid was added thereto, and the mixture was stirred at room temperature for 2 hours. The methylene chloride was removed under reduced pressure, and the residue was crystallised from ethyl acetate (EtOAc). Add it to acetone, add appropriate amount of perchloric acid, stir at room temperature for 24 hours, adjust the pH to neutral with saturated sodium bicarbonate solution, distill off acetone under reduced pressure, extract with dichloromethane, dry over anhydrous sodium sulfate, decompress Concentration gave a white solid (X).
(6) 与实施 1的步骤 (6) 相同。  (6) Same as step (6) of implementation 1.
实施例 3 Example 3
胆甾一 3β,5α, 6β,19—四羟基一 i24—酮的合成 (1)〜(4) 与实施例 1的步骤(1) ~ (4) 相同。 Synthesis of cholestyl-3β,5α, 6β,19-tetrahydroxy-i24-one (1) to (4) The same as steps (1) to (4) of the first embodiment.
(5)取化合物 (VI)加入 88%甲酸溶解 (浓度约为 5%) ,沸水浴加热 5 分钟, 冷却至室温, 加入 30%过氧化氢溶液, 室温放置 24小时, 用水稀释后, 用乙酸乙酯萃取, 然后加 10%亚硫酸钠溶液洗涤至无色, 水洗至中性, 无水硫酸 钠干燥, 减压浓缩, 得白色固体(Kb)。  (5) Take compound (VI) dissolved in 88% formic acid (concentration is about 5%), heat in boiling water bath for 5 minutes, cool to room temperature, add 30% hydrogen peroxide solution, let stand at room temperature for 24 hours, dilute with water, use acetic acid The ethyl ester was extracted and washed with aq. EtOAc (EtOAc) (EtOAc)
(6)将上步产物 (Kb) lg加到 500L3%的氢氧化钾甲醇溶液, 加热回流 30分钟, 用 5%盐酸调整溶液的 pH为中性, 减压蒸馏除去甲醇, 乙酸乙酯萃取 三次, 有机层合并用无水硫酸钠干燥, 减压蒸去溶剂, 得浅黄色固体, 硅胶柱层 析, 得白色固体 (1)。 '  (6) Add the above product (Kb) lg to 500 L of 3% potassium hydroxide in methanol, heat to reflux for 30 minutes, adjust the pH of the solution to neutral with 5% hydrochloric acid, distill off methanol under reduced pressure, and extract with ethyl acetate three times. The organic layer was dried over anhydrous sodium sulfate (MgSO4). '
实施例 4 Example 4
24—亚甲基一胆甾一3β,5α, 6]β,19一四醇的合成  Synthesis of 24-methylene-cholesteryl-3β,5α,6]β,19-tetraol
(1)〜(6) 与实施例 1的步骤(1) ~ (6)相同。  (1) to (6) The same as steps (1) to (6) of the first embodiment.
(7)在 50mL无水四氢呋喃溶液中加入 2克甲基三苯基溴化膦, 通氮气, 注入适量的正丁基锂, 室温下搅拌反应 6小时, 将 1克' (I) 的四氢呋喃溶液注 入反应体系, 继续反应 2小时, 将反应液迅速倒入饱和的氯化铵溶液中, 用乙醚 萃取, 醚层用无水硫酸钠干燥, 减压蒸去溶剂, 得浅黄色固体, 硅胶柱层析, 得 白色固体(11)。  (7) Add 2 g of methyltriphenylphosphonium bromide in 50 mL of anhydrous tetrahydrofuran solution, pass nitrogen gas, inject an appropriate amount of n-butyllithium, and stir the reaction at room temperature for 6 hours to give 1 g of '(I) tetrahydrofuran solution. The reaction mixture was poured into the reaction system, and the reaction was continued for 2 hours. The reaction solution was poured into a saturated ammonium chloride solution and extracted with diethyl ether. The ether layer was dried over anhydrous sodium sulfate. Analysis gave a white solid (11).
实施例 5 Example 5
胆甾一 3β,5α, 6β, 19—四羟基一24—双腙的合成  Synthesis of cholesteric 3β,5α, 6β, 19-tetrahydroxy-24-biguanide
(1)〜(6) 与实施例 1的步骤(1) ~ (6) 相同。  (1) to (6) are the same as steps (1) to (6) of the first embodiment.
(7)将 1克(I)用 10mL乙醇溶解, 加入 lmL50%肼的水溶液, 加热回流 4小时, 减压蒸去溶剂, 加入适量水, 调 pH为中性, 乙酸乙酯萃取, 得白色固 体, 硅胶柱层析, 得白色固体(111)。 - 实施例 6  (7) 1 g (I) was dissolved in 10 mL of ethanol, and 1 mL of a 50% hydrazine aqueous solution was added thereto, and the mixture was heated under reflux for 4 hours. The solvent was evaporated under reduced pressure, and the mixture was adjusted to pH. Silica gel column chromatography gave white solid (111). - Example 6
胆甾— 3β,5α, 6β,19—四羟基 _24—双腙的合成  Cholesterol - Synthesis of 3β, 5α, 6β, 19-tetrahydroxy _24-biguanide
(1)〜(6) 与实施例 1的步骤(1) - (6) 相同。  (1) to (6) are the same as steps (1) to (6) of the embodiment 1.
(7)将 1克(I)用 20mL乙醇溶解, 加入 lmL80%肼的水溶液, 加热回流 2小时, 减压蒸去溶剂, 加入适量水, 调 pH为中性, 乙酸乙酯萃取, 得白色固 体, 硅胶柱层析, 得白色固体(m)。 目的产物 h 胆甾一 3β,5α, 6β, 19一四羟基一 24—酮的结构确证 (7) 1 g (I) was dissolved in 20 mL of ethanol, and 1 mL of an 80% aqueous solution of hydrazine was added thereto, and the mixture was heated under reflux for 2 hours. The solvent was evaporated under reduced pressure, and the mixture was adjusted to pH. Silica gel column chromatography gave white solid (m). Structural confirmation of the target product h cholestyr-3β,5α, 6β, 19-tetrahydroxy-24-ketone
熔点: 213—214°C Melting point: 213-214 ° C
元素分析: C27H«05 测定值: C, 71.60; H, 20.50; 理论值: C, 71.92; H, 10.29, MS: [M + Na] + = 473 Elemental analysis: C 27 H «0 5 Measured: C, 71.60; H, 20.50; Theory: C, 71.92; H, 10.29, MS: [M + Na] + = 473
IR: 3324, 2941, 2889, 1708, 1464, 1380, 1342, 1048, 975. IR: 3324, 2941, 2889, 1708, 1464, 1380, 1342, 1048, 975.
1HNMR(DMSO): 1H NMR (DMSO):
3.99 (IH, d, 19-CH) , 3.86 (ra, IH, 3 β一 CH) , 3.52 (IH, in, 19-CH) , 3.23 (m, IH, 60一 CH) , 2.59 (IH, m, 25 - CH) , 1.18 (3H, d, 26—C¾, 27-CH3) , 1.01 (3H, s, 19— CH3) , 0.87 (3H, d ,21- C¾),0.65 (3H, s, 18-C¾). 3.99 (IH, d, 19-CH), 3.86 (ra, IH, 3 β-CH), 3.52 (IH, in, 19-CH), 3.23 (m, IH, 60-CH), 2.59 (IH, m , 25 - CH) , 1.18 (3H, d, 26-C3⁄4, 27-CH 3 ) , 1.01 (3H, s, 19-CH 3 ) , 0.87 (3H, d , 21- C3⁄4), 0.65 (3H, s , 18-C3⁄4).
13CNMR(DMSO): 1 3 C NMR (DMSO):
214.2(C), 74.5(0, 73.8 (CH) , 65.8 (CH) , 62.0 (CH2) , 56.5 (CH) , 55.5 (CH) , 44.9(CH), 42.53(C), 42.47 (CH), 41.0(C), 40.3(CH2), 39.8 (CH) , 36.4(CH), 34.9 (CH2) , 33.9 (CH2) , 31.1(CH2), 30.8(CH2), 29.3 (CH2) , 27.7 (CH2) , 26.8 (CH2) , 23.8(CH2), 21.7(CH3), 18.3(C¾), 18.1(CH3), 18.0(CH3), 13.1(CH3). 目的产物 2: 24-亚甲基一胆甾一3 5(i, 6β, 19—四醇的结构确证 214.2(C), 74.5(0, 73.8 (CH), 65.8 (CH), 62.0 (CH 2 ), 56.5 (CH), 55.5 (CH), 44.9 (CH), 42.53(C), 42.47 (CH), 41.0(C), 40.3(CH 2 ), 39.8 (CH) , 36.4 (CH), 34.9 (CH 2 ) , 33.9 (CH 2 ) , 31.1 (CH 2 ), 30.8 (CH 2 ), 29.3 (CH 2 ) , 27.7 (CH 2 ), 26.8 (CH 2 ), 23.8 (CH 2 ), 21.7 (CH 3 ), 18.3 (C3⁄4), 18.1 (CH 3 ), 18.0 (CH 3 ), 13.1 (CH 3 ). 2: 24-Methylene-cholesteryl- 3 5 (i, 6β, 19-tetraol structure confirmation
熔点: 223— 225 °C ' Melting point: 223-225 °C '
元素分析: C28H4804 测定值: C, 75.20; H, 10.36 理论值: C, 74.95; H, 10.78, MS: [M-H20]+=432, Elemental analysis: C 28 H 48 0 4 Measured: C, 75.20; H, 10.36 Theory: C, 74.95; H, 10.78, MS: [MH 2 0] + = 432,
IR: 3416, 3028, 2936, 2868, 1642,1464, 1377, 1057 IR: 3416, 3028, 2936, 2868, 1642, 1464, 1377, 1057
^NMRiDMSO): ^NMRiDMSO):
5.25 (IH, d, 6 β - OH), 4.71 (IH, d, - 5Hz, 28- CH), 4.65 (IH, d, J=l.5Hz, 28- CH) , 5.25 (IH, d, 6 β - OH), 4.71 (IH, d, - 5Hz, 28- CH), 4.65 (IH, d, J=l.5Hz, 28- CH) ,
4.51(lH,d, 19-OH), 4.16(1H, d, 3—CH), 4.01 (IH, d, 19-CH), 3.8 (IH, ra, 3-CH), 3.64 (IH, s, 5-0H), 3.23 (lH,m, 6—CH), 2.25 (IH, m, 25- CH) , 4.51(lH,d, 19-OH), 4.16(1H, d, 3—CH), 4.01 (IH, d, 19-CH), 3.8 (IH, ra, 3-CH), 3.64 (IH, s, 5-0H), 3.23 (lH,m, 6-CH), 2.25 (IH, m, 25- CH) ,
1.13 (6H, d, 26— C , 27-CH3) , 1.01 (3H, s, 19— CH3), 0.87 (3H, d, 21— CH3) , 0.67(3H, s, 18-C¾) . 1.13 (6H, d, 26-C, 27-CH 3 ) , 1.01 (3H, s, 19-CH 3 ), 0.87 (3H, d, 21-CH 3 ) , 0.67 (3H, s, 18-C3⁄4) .
13CNMR(DMSO): 1 3 C NMR (DMSO):
156.6(C), 107.3 (CH2) , 75.4(C), 74.7 (CH) , 66.7 (CH) , 63.0(CH2), 57.4(CH), 56.7(CH), 45.9(CH), 43.5(C), 43.3(CH), 42.8(C), 41.3(CH2), 40.9(CH), 37.4(CH2), 36.1 (CH) , 33.9(C¾), 31.8(C¾), 31.4(CH2), 30.5(CH2), 28.7(CH2), 27.9 (C¾) , 24.70(CH2), 22.64(CH3), 22.57 (CH3) , 19.4(CH3), 13.1 (CH3) . 目的产物 3: 胆甾一 3β,5α, 6 e, 19—四轻基一 24—双腙的结构确证 156.6(C), 107.3 (CH 2 ), 75.4(C), 74.7 (CH), 66.7 (CH), 63.0(CH 2 ), 57.4(CH), 56.7(CH), 45.9(CH), 43.5(C ), 43.3(CH), 42.8(C), 41.3(CH 2 ), 40.9(CH), 37.4 (CH 2 ), 36.1 (CH), 33.9 (C3⁄4), 31.8 (C3⁄4), 31.4 (CH 2 ), 30.5 (CH 2 ), 28.7 (CH 2 ), 27.9 (C3⁄4), 24.70 (CH 2 ), 22.64(CH 3 ), 22.57 (CH 3 ) , 19.4(CH 3 ), 13.1 (CH 3 ) . The target product 3: the structure of cholestyl-3β,5α, 6 e, 19-tetra-light-one-bi-indole Confirmation
熔点: 270-272 °C Melting point: 270-272 °C
元素分析: C54H0 测定值: C, 70.92; H, 10.44; N, 2.98 理论值: C, 72.27; Elemental analysis: C 54 H 0 Measured: C, 70.92; H, 10.44; N, 2.98 Theory: C, 72.27;
H, 10.33; N, 3.12 - MS: [M+l]+=897 H, 10.33; N, 3.12 - MS: [M+l] + =897
IR: 3318, 2943, 2870, 1628, 1464, 1379, 1344, 1060, 976c  IR: 3318, 2943, 2870, 1628, 1464, 1379, 1344, 1060, 976c
1HNMR(DMSO): 1H NMR (DMSO):
5.38 (1H, ί,6 一 H) , 4.71 (1H, d, J l- 5Hz, 28-CH), 4.65 (1H, d, J=l.5Hz, 28- CH) , 3. 52 (IH, m, 3-CH), 2.28 (1H, m, 25- CH) , 1.13'(6H, d, 26-C¾, 27 - CH3) , 1.01 (3H, s, 19- C H3), 0.91 (3H, d, 21-CH3), 0.69 (3H, s, 18- CH3) . 5.38 (1H, ί,6-H), 4.71 (1H, d, J l- 5Hz, 28-CH), 4.65 (1H, d, J=l.5Hz, 28-CH), 3. 52 (IH, m, 3-CH), 2.28 (1H, m, 25-CH) , 1.13'(6H, d, 26-C3⁄4, 27 - CH 3 ) , 1.01 (3H, s, 19- CH 3 ), 0.91 (3H , d, 21-CH 3 ), 0.69 (3H, s, 18- CH 3 ) .
13CNMR(DMSO): 1 3 C NMR (DMSO):
169.3(0,75.4(0, 74.7 (CH) , 66.8(CH), 63.6(CH2), 57.5 (CH) , 56.4(CH), 45.9 (CH) , 43.5(C), 42.8(C), 41.3(CH2), 40.8 (CH) , 37.4(CH2), 35.8 (CH) , 35.6 (CH2) , 33.9 (CH2) ,31.8 (CH2) ,31.4(CH2) , 30.5 (CH2) , 28.7 (CH2) , 27.9 (CH2) , 24.70 (CH2), 22.5 (CH3) ,21.4 (CH3), 19.2 (CH3) , 18.9 (CH3) , 13.1 (CH3) . 169.3 (0,75.4 (0, 74.7 (CH), 66.8 (CH), 63.6 (CH 2 ), 57.5 (CH), 56.4 (CH), 45.9 (CH), 43.5 (C), 42.8 (C), 41.3 (CH 2 ), 40.8 (CH) , 37.4 (CH 2 ), 35.8 (CH), 35.6 (CH 2 ) , 33.9 (CH 2 ) , 31.8 (CH 2 ) , 31.4 (CH 2 ) , 30.5 (CH 2 ) , 28.7 (CH 2 ) , 27.9 (CH 2 ) , 24.70 (CH 2 ), 22.5 (CH 3 ) , 21.4 ( CH 3 ) , 19.2 ( CH 3 ) , 18.9 ( CH 3 ) , 13.1 ( CH 3 ) .

Claims

权 利 要 求 Rights request
1. 一种胆甾一 3β, 5α, 6β, 19一四羟基一 24—酮及衍生物的合成方法, 其 特征是以猪去氧胆酸为原料, 制备 3 β—乙酰氧基一胆甾一 5—烯一 24—酸, 通 过和氯化亚砜反应制备成胆 酰氯, 超声波辐射下和异丙基镉试剂反应得 3 β— 乙酰氧基一胆甾一 5—烯一 24—酮, 再与 Ν—溴代丁二酰亚胺 /高氯酸水溶液体系 反应得到 3 β—乙酰氧基一胆甾一 5 α一溴一 6 β—羟基—24—酮,之后用二乙酰 氧基碘代苯生成 3 β—乙酰氧基一胆甾 _5 α—溴一 6 β, 19一环氧—24—酮, 用 锌粉 /冰醋酸体系还原生成 3 β, 19一二乙酰氧基一胆甾一5—烯一 24—酮; 再用 氧化剂氧化 5, 6位双键, 水解反应得胆 一 3β, 5α, 6β, 19一四羟基一 24—酮; 最后和甲基三苯基溴化膦反应合成 24—亚甲基一胆甾一 3 β, 5 α , 6 β , 19—四 醇; 和肼反应合成胆甾一 3β,5α, 6β,19—¾羟基一 24—双腙。 A method for synthesizing cholesteric-3β, 5α, 6β, 19-tetrahydroxy-24-ketone and a derivative thereof, characterized in that porphyoxycholic acid is used as a raw material to prepare 3 β-acetoxy-cholesteryl 5-ene-24-acid, prepared by reacting with thionyl chloride to prepare choline chloride, and reacting with isopropyl cadmium reagent under ultrasonic irradiation to obtain 3β-acetoxy-cholester-5-ene-24-one. Reaction with hydrazine-bromosuccinimide/perchloric acid aqueous solution system to obtain 3β-acetoxy-cholesteryl-5 α-bromo-6β-hydroxy- 24 -ketone, followed by diacetoxyiodo Benzene produces 3 β-acetoxy-cholesterol_5 α-bromo-6β, 19-epoxy-24-ketone, which is reduced by zinc powder/glacial acetic acid system to form 3β,19-diacetoxy-cholesteryl a 5-alkenyl-2-ketone; oxidizing 5, 6 double bonds with an oxidizing agent, hydrolyzing to give 3β, 5α, 6β, 19-tetrahydroxy-24-one; and finally methyltriphenylphosphonium bromide The reaction synthesizes 24-methylene-cholesterol-3β, 5α, 6β, 19-tetraol; and hydrazine reacts to synthesize cholesteric-3β, 5α, 6β, 19-3⁄4 hydroxy-24-biguanide.
2. 根据权利要求 1所述的合成方法, 其特征是具体的反应步骤为:  2. The method of synthesis according to claim 1, wherein the specific reaction steps are:
( 1 ) 将 IV溶于无水苯加入氯化亚砜, 加入催化量的吡啶, 在室温下搅拌 2〜 4小时, 减压浓缩至干, 再补加苯继续浓缩, 带出残留的氯化亚砜, 得黄色粘稠 的液体;  (1) Add IV to anhydrous benzene to thionyl chloride, add a catalytic amount of pyridine, stir at room temperature for 2 to 4 hours, concentrate to dryness under reduced pressure, and add benzene to continue concentration to bring out residual chlorination. Sulfoxide, a yellow viscous liquid;
(2) 称取干燥镁粉, 加入无水乙醚, 滴加异溴丙烷 /无水乙醚溶液, 加完后 超声辐射 15〜30分钟, 冷却后分批加入氯化镉, 在 25〜40°C下在超声波辐射下 搅拌, 冰浴冷却下, 将上步产物的 30〜40%无水苯溶液慢慢滴加到反应体系中, 滴完后继续超声波辐射回流 1〜2小时, 冰浴冷却后, 滴加 1 : 1盐酸水溶液, 用 苯萃取, 苯层用蒸馏水洗至中性, 干燥, 减压浓缩, 硅胶柱层析, 得白色固体 V; (2) Weigh dry magnesium powder, add anhydrous ether, add isobromopropane / anhydrous ether solution, add ultrasonic radiation for 15~30 minutes, add cadmium chloride in batches after cooling, at 25~40 °C Under the ultrasonic irradiation, the 30~40% anhydrous benzene solution of the above step product is slowly added dropwise to the reaction system after the ice bath is cooled. After the completion of the dropping, the ultrasonic irradiation is continued for 1 to 2 hours, and the ice bath is cooled. , adding 1 : 1 hydrochloric acid aqueous solution, extracted with benzene, the benzene layer was washed with distilled water until neutral, dried, concentrated under reduced pressure, silica gel column chromatography to give a white solid V;
(3 ) 取白色固体 V, 加入有机溶剂溶解, 再加入 HC104及水, 然后在避光 条件下分批加入 N—丁二酰亚胺, 控制温度低于 10°C, 之后在 15〜20°C下反应 1〜2小时, 向反应液中加入 10%Na2S2O8 水溶液, 分层后, 上层浓缩, 下层用 CH2C12萃取, 合并有机层, 用饱和 NaHC03溶液洗涤, 再用蒸馏水洗涤至中性, 干燥, 减压浓缩, 硅胶柱层析, 得白色固体 VI; (3) Take a white solid V, add organic solvent to dissolve, add HC10 4 and water, then add N-succinimide in portions in the dark, control the temperature below 10 ° C, then at 15~20 after the reaction at ° C 1~2 hours, was added 10% Na 2 S 2 O 8 was added to the reaction solution, the layers were separated, the upper layer was concentrated, the lower layer was extracted with CH 2 C1 2, the organic layers were combined, washed with saturated NaHC0 3 solution, Washing with distilled water until neutral, drying, concentration under reduced pressure, silica gel column chromatography to give a white solid VI;
(4) 取化合物 VI, 溶入环已垸 /苯混合液, 加入氧化剂, 20〜40°C搅拌下, 紫外灯照射 7〜8小时, 反应液依次用 10%硫代硫酸钠水溶液, 饱和 NaHC03溶 液及蒸熘水洗涤至中性, 干燥, 减压浓缩得浅黄色化合物 W; (4) Take compound VI, dissolve in cyclohexane/benzene mixture, add oxidant, stir at 20~40 °C, irradiate with UV lamp for 7~8 hours, and then use 10% aqueous sodium thiosulfate solution, saturated NaHC0. 3 solution and distilled water to wash to neutral, dry, concentrated under reduced pressure to give a pale yellow compound W;
(5) 取化合物珊加入冰醋酸溶解, 加入锌粉, 搅拌回流 20〜24小时; 趁热 抽滤,滤液用二氯甲烷萃取,萃取液分别角饱和碳酸氢钠溶液及蒸馏水洗至中性, 干燥, 减压浓缩, 硅胶柱层析, 得浅黄色粘稠液体珊; (5) Take the compound and add it to the glacial acetic acid to dissolve, add the zinc powder, and stir to reflux for 20 to 24 hours; After suction filtration, the filtrate was extracted with dichloromethane, and the extract was washed with a saturated aqueous sodium hydrogen carbonate solution and distilled water to neutral, dried, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain a pale yellow viscous liquid.
(6) 取化合物 VI加入二氯甲烷溶解, 加入氧化剂, 室温下搅拌, 减压除去 二氯甲垸, 渣块用乙酸乙酯溶解, 然后加 10%亚硫酸钠溶液洗涤至无色, 水洗至 中性, 干燥, 减压浓缩, 得白色固体 IXa, 将其加入丙酮溶解, 加入高氯酸, 室 温下搅拌, 调 pH至中性, 减压蒸去丙酮, 用二氯甲垸萃取, 干燥, 减压浓缩, 得白色固体 X;  (6) Compound VI is added to methylene chloride to dissolve, oxidizing agent is added, stirring at room temperature, dichloromethane is removed under reduced pressure, the residue is dissolved in ethyl acetate, and then washed with 10% sodium sulfite solution until colorless, washed with water until neutral. , dry, concentrated under reduced pressure to give white solid IXa, which is dissolved in acetone, added with perchloric acid, stirred at room temperature, adjusted to pH neutral, acetone evaporated under reduced pressure, extracted with dichloromethane, dried, decompressed Concentrated to give a white solid X;
(7)取化合物 加入 88%甲酸溶解, 沸水浴加热 5分钟, 冷却至室温, 加 入氧化剂, 室温放置 24小时, 用水稀释后, 用乙酸乙酯萃取, 然后加 10%亚硫 酸钠溶液洗涤至无色, 水洗至中性, 干燥, 减压浓缩, 得白色固体 Kb;  (7) The compound was dissolved in 88% formic acid, heated in a boiling water bath for 5 minutes, cooled to room temperature, added with an oxidizing agent, allowed to stand at room temperature for 24 hours, diluted with water, extracted with ethyl acetate, and then washed with 10% sodium sulfite solution until colorless. Washed to neutral, dried, concentrated under reduced pressure to give a white solid Kb;
( 8 )将上步产物 Kb或 X溶解在甲醇中,加入浓度为 3 %的氢氧化钾醇溶液, 加热回流 15〜30分钟, 调 pH为中性, 减压蒸馏除去甲醇, 乙酸乙酯萃取, 有 机层干燥, 减压蒸去溶剂, 得浅黄色固体, 硅胶柱层析, 得白色固体 I;  (8) Dissolve the above-mentioned product Kb or X in methanol, add a 3% potassium hydroxide alcohol solution, heat to reflux for 15 to 30 minutes, adjust the pH to neutral, distill off methanol under reduced pressure, and extract with ethyl acetate. , the organic layer is dried, the solvent is evaporated under reduced pressure to give a pale yellow solid.
(9) 将甲基三苯基溴化膦加入无水四氢呋喃溶液中, 注入正丁基锂, 注入 量以甲基三苯基溴化膦刚好溶解为宜, 室温下搅拌反应 4〜6小时, 将上步中的 (9) Add methyltriphenylphosphonium bromide to an anhydrous tetrahydrofuran solution, and inject n-butyllithium. The amount of the injection is preferably dissolved in methyltriphenylphosphonium bromide, and the reaction is stirred at room temperature for 4 to 6 hours. Will be in the previous step
I加入反应体系, 继续反应 2〜3小时, 将反应液迅速倒入饱和的氯化铵溶液中, 用乙醚萃取, 醚层干燥, 减压蒸去溶剂, 得浅黄色固体, 硅胶柱层析, 得白色固 体 II; I, the reaction system is added to the reaction system, and the reaction is continued for 2 to 3 hours. The reaction solution is poured into a saturated ammonium chloride solution, and extracted with diethyl ether. The ether layer is dried, and the solvent is evaporated to give a pale yellow solid. Obtained a white solid II;
( 10) 将 I加入乙醇溶解, 加入肼的水溶液中, 解热回流, 减压蒸去溶剂, 加入水, 调 pH为中性, 乙酸乙酯萃取, 得白色固体, 硅胶柱层析, 得白色固体 (10) I was dissolved in ethanol, added to an aqueous solution of hydrazine, and refluxed under reduced pressure. The solvent was evaporated under reduced pressure. Water was added, and the mixture was adjusted to neutral, and ethyl acetate was evaporated to give a white solid. solid
III; III;
上述步骤中, I代表胆甾一 3 P,5 ci, 6 β,19—四羟基一 24—酮; Π代表 24 一亚甲基一胆甾一 3 β , 5 α, 6 β,19一四醇; III代表 胆甾一 3 β , 5 α, 6 β , 19— 四羟基—24—双腙; IV代表 3 β—乙酰氡基—胆甾一 5—烯一 24—酸; V代表 3 β—乙酰氧基一胆甾一 5—烯一 24—酮; "VI代表 3 β—乙酰氧基一胆甾— 5 α—溴 —6 β—羟基一 24—酮; W代表 3 β—乙酰氧基一胆甾一 5 α—溴一 6 19—环 氧一 24—酮;珊代表 3 β, 19一二乙酰氧基一胆甾一5—烯一 24—酮; IXa代表 3 β , 19—二乙酰氧基一胆甾一 5, 6 β—环氧一24—酮; Kb代表 3 β, 19一二乙 酰氧基一胆甾一5, 6 α—环氧一 24—酮;' X代表 3 β, 19—二乙酰氧基一胆甾一 5, 6—二羟基—24—酮。 In the above steps, I represents cholestyl-3 P,5 ci, 6 β,19-tetrahydroxy-24-one; Π represents 24-methylene-cholesteryl-3β, 5α, 6β,19-14 Alcohol; III represents cholesteryl-3β, 5α, 6β, 19-tetrahydroxy-24-biguanide; IV represents 3β-acetylindolyl-cholester-5-ene-24-acid; V represents 3 β -Acetoxy-cholesteryl-5-ene-24-one; "VI stands for 3β-acetoxy-cholesterium-5α-bromo-6β-hydroxy-24-one; W stands for 3β-acetoxy Base one cholesteryl-5 α-bromo-6 epoxide-epoxy-24-ketone; Shan represents 3 β, 19-diacetoxy-cholesteryl 5-alkenyl 24-ketone; IXa stands for 3 β , 19 — Diacetoxy-cholesteryl-5,6β-epoxy-24-one; Kb stands for 3β,19-diacetoxy-cholesteryl-5,6α-epoxy-24-one; 'X stands for 3 β, 19-diacetoxy-cholesteryl 5,6-dihydroxy-24-ketone.
3. 根据权利要求 2所述的合成方法, 其特征是步骤 (1 ) 中 II的苯溶液的 浓度是 25〜45 %, 氯化亚砜的量是 II的摩尔数的 1.0〜2.0倍。  The synthesis method according to claim 2, wherein the concentration of the benzene solution of II in the step (1) is 25 to 45%, and the amount of the thionyl chloride is 1.0 to 2.0 times the number of moles of II.
4. 根据权利要求 2 所述的合成方 , 其特征是步骤 (2) 中镁粉的量是 II 的摩尔数的 1.2〜3.0倍。  The synthetic side according to claim 2, wherein the amount of the magnesium powder in the step (2) is 1.2 to 3.0 times the number of moles of II.
5. 根据权利要求 2所述的合成方法, 其特征是步骤(3 ) 中的有机溶剂为四 氢呋喃或二氧六环。  The method according to claim 2, wherein the organic solvent in the step (3) is tetrahydrofuran or dioxane.
6. 根据权利要求 2所述的合成方法, 其特征是步骤(4) 中的氧化剂为二乙 酰氧基碘代苯或四醋酸铅。 - 6. The method according to claim 2, wherein the oxidizing agent in the step (4) is diacetoxyiodobenzene or lead tetraacetate. -
7. 根据权利要求 2所述的合成方法, 其特征是步骤(6) 中的氧化剂为高锰 酸钾 /硫酸铜或间氯过苯甲酸。 7. The method according to claim 2, wherein the oxidizing agent in the step (6) is potassium permanganate / copper sulfate or m-chloroperbenzoic acid.
8. 根据权利要求 2所述的合成方法, 其特征是步骤 (7) 中的氧化剂为 30 %双氧水。  8. The method of synthesis according to claim 2, wherein the oxidizing agent in the step (7) is 30% hydrogen peroxide.
PCT/CN2006/001627 2005-12-31 2006-07-10 METHOD FOR SYNTHESIS OF CHOLEST-3β,5α,6β,19-TETRAHYDROXY-24-ONE AND ITS DERIVATIVES WO2007076655A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006332419A AU2006332419A1 (en) 2005-12-31 2006-07-10 The use of phthalide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200510121374.X 2005-12-31
CNB200510121374XA CN100436474C (en) 2005-12-31 2005-12-31 Process for synthesizing cholester-3 bata, 5 alpha, 6 bata, 19-tetrahydroxy-24-one and derivative

Publications (1)

Publication Number Publication Date
WO2007076655A1 true WO2007076655A1 (en) 2007-07-12

Family

ID=36804818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/001627 WO2007076655A1 (en) 2005-12-31 2006-07-10 METHOD FOR SYNTHESIS OF CHOLEST-3β,5α,6β,19-TETRAHYDROXY-24-ONE AND ITS DERIVATIVES

Country Status (2)

Country Link
CN (1) CN100436474C (en)
WO (1) WO2007076655A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114671796A (en) * 2022-04-22 2022-06-28 宁波工程学院 Method for synthesizing N-alkyl phthalimide through photocatalysis

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104497086B (en) * 2014-12-12 2016-08-17 中山大学 Androstane-3 β, 5 α, 6 β, 19-tetrol and preparation method and application
CN106146593B (en) * 2015-04-14 2021-06-01 南京迈诺威医药科技有限公司 Method for preparing deoxycholic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637691A (en) * 1993-03-10 1997-06-10 Magainin Pharmaceuticals, Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
CN1448400A (en) * 2003-05-06 2003-10-15 中山大学 Synthetic method of 24-methylene-cholesterol-3 beta, 5 alpha, 6 beta,19-tetraalcohol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5573700A (en) * 1978-11-30 1980-06-03 Teijin Ltd Preparation of steroidal ketone compound
CN1448399A (en) * 2003-04-24 2003-10-15 中山大学 Synthetic method of 24-methylene-cholesterol-5-alkenyl-3 beta, 19-glycol
CN1583782A (en) * 2004-05-28 2005-02-23 中山大学 Synthesis of 24-submethyl-cholesterol-5-ene-3 beta, 7 beta, 19-trialcohol
CN1583781A (en) * 2004-05-28 2005-02-23 中山大学 Synthesis of 3 beta, 7 beta, 19-tricarboxy-5-ene-cholestane

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637691A (en) * 1993-03-10 1997-06-10 Magainin Pharmaceuticals, Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
CN1448400A (en) * 2003-05-06 2003-10-15 中山大学 Synthetic method of 24-methylene-cholesterol-3 beta, 5 alpha, 6 beta,19-tetraalcohol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORIARTY R. ET AL.: "Synthesis of squalamine. A steroidal antibiotic from the shark", TETRAHEDRON LETT., vol. 35, no. 44, 1994, pages 8103 - 8106, XP000572370 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114671796A (en) * 2022-04-22 2022-06-28 宁波工程学院 Method for synthesizing N-alkyl phthalimide through photocatalysis
CN114671796B (en) * 2022-04-22 2024-06-11 宁波工程学院 Method for synthesizing N-alkyl phthalimide by photocatalysis

Also Published As

Publication number Publication date
CN1793159A (en) 2006-06-28
CN100436474C (en) 2008-11-26

Similar Documents

Publication Publication Date Title
US4183852A (en) Process for preparing 25-hydroxycholesterol
US4425273A (en) Process for production of chenodeoxycholic acid
NL8320153A (en) PROCESS FOR PREPARING 26,26,26,27,27,27, HEXAFLUOR-1ALFA, 25-DIHYDROXYCHOLESTEROL.
WO2007076655A1 (en) METHOD FOR SYNTHESIS OF CHOLEST-3β,5α,6β,19-TETRAHYDROXY-24-ONE AND ITS DERIVATIVES
AU775831B2 (en) Process for preparing 17alpha-acetoxy-11beta-(4-N,N-(dimethylamino)phenyl)-21- methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
US20220372065A1 (en) Synthesis of cholesterol and vitamin d3 from phytosterols
CN115466300A (en) Cholic acid intermediate A7 and synthesis method thereof
WO2007076656A1 (en) METHOD FOR SYNTHESIS OF CHOLEST-5-EN-3β,19-DIHYDROXY-24-ONE AND ITS DERIVATIVES
JP2004307390A (en) Method for producing steroid compound
JPH0122278B2 (en)
CN115611961B (en) Cholic acid intermediate A2 and preparation method thereof
US4145357A (en) Steroid derivatives and process for preparing the same
EP0013082A1 (en) Process for producing steroid compounds having an oxogroup in the side chain
CN115651049B (en) Cholic acid intermediate A3 and preparation method thereof
CN116023424B (en) Cholic acid intermediate A4 and preparation method thereof
CN115536720B (en) Cholic acid intermediate A8 and preparation method thereof
JPS6148499B2 (en)
US20070129558A1 (en) Monohalogenovinyl vitamin d derivative compounds
JPS623840B2 (en)
JP2953665B2 (en) Method for producing steroid derivative
JP3228486B2 (en) Hydroxyketone derivative and method for producing the same
JPS6310720B2 (en)
JPS6148498B2 (en)
JPS6126555B2 (en)
JPS6214560B2 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006332419

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006332419

Country of ref document: AU

Date of ref document: 20050930

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006332419

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06761387

Country of ref document: EP

Kind code of ref document: A1